Four-way, multicenter, crossover trial of ibuprofen, fenoprofen calcium, naproxen, and tolmetin sodium in osteoarthritis: comparative clinical profiles.
One hundred forty-one subjects with osteoarthritis completed this double-blind, multicenter, crossover trial comparing four nonsteroidal anti-inflammatory (NSAI) agents after single-blind aspirin stabilization. Preferences of both patients and physicians showed the following rank order from most to least preferable: tolmetin sodium, naproxen, ibuprofen, fenoprofen calcium. By all but three of more than 20 measures of efficacy, tolmetin sodium and naproxen were the more effective pair and fenoprofen calcium and ibuprofen the less effective pair of the four. Eight of nine measures of tolerability suggested the following rank order from best to worst tolerated: ibuprofen, naproxen, tolmetin sodium, fenoprofen calcium, aspirin. Few differences among the newer NSAI agents compared in this study achieved statistical significance. Nevertheless, the tolerability-efficacy relationships that emerge from studies of this type can help to define rational approaches to the use of these drugs in rheumatic diseases.
D000328:Adult; D000368:Aged; D001241:Aspirin / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004361:Drug Tolerance; D005260:Female; D005279:Fenoprofen / Q000627:therapeutic use*; D006801:Humans; D007052:Ibuprofen / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009288:Naproxen / Q000627:therapeutic use*; D010003:Osteoarthritis / Q000188:drug therapy*; D010666:Phenylpropionates / Q000627:therapeutic use*; D011758:Pyrroles / Q000627:therapeutic use*; D014046:Tolmetin / Q000627:therapeutic use*
D010666:Phenylpropionates; D011758:Pyrroles; D009288:Naproxen; D014046:Tolmetin; D001241:Aspirin; D005279:Fenoprofen; D007052:Ibuprofen